Eagle Asset Management Inc. grew its stake in Genomic Health, Inc. (NASDAQ:GHDX) by 76.9% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 457,993 shares of the medical research company’s stock after buying an additional 199,053 shares during the quarter. Eagle Asset Management Inc. owned 1.22% of Genomic Health worth $31,061,000 as of its most recent SEC filing.
Several other hedge funds also recently modified their holdings of the company. Alps Advisors Inc. acquired a new position in shares of Genomic Health in the 3rd quarter valued at about $347,000. Creative Planning acquired a new position in shares of Genomic Health in the 3rd quarter valued at about $405,000. Gabelli Funds LLC acquired a new position in shares of Genomic Health in the 3rd quarter valued at about $2,041,000. GABELLI & Co INVESTMENT ADVISERS INC. acquired a new position in shares of Genomic Health in the 3rd quarter valued at about $2,584,000. Finally, LS Investment Advisors LLC acquired a new position in shares of Genomic Health in the 3rd quarter valued at about $48,000. 93.16% of the stock is owned by institutional investors and hedge funds.
NASDAQ GHDX traded down $0.44 during trading hours on Friday, reaching $63.44. The company’s stock had a trading volume of 12,537,000 shares, compared to its average volume of 435,103. The company has a debt-to-equity ratio of 0.15, a current ratio of 5.96 and a quick ratio of 5.96. The company’s 50-day moving average is $68.48 and its two-hundred day moving average is $64.47. Genomic Health, Inc. has a 1-year low of $50.77 and a 1-year high of $90.18. The firm has a market capitalization of $2.46 billion, a price-to-earnings ratio of 60.42 and a beta of 0.90.
In other Genomic Health news, COO Frederic Pla sold 1,251 shares of the company’s stock in a transaction on Monday, August 19th. The stock was sold at an average price of $75.00, for a total transaction of $93,825.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Laura Leber sold 13,183 shares of the company’s stock in a transaction on Thursday, October 17th. The stock was sold at an average price of $70.94, for a total value of $935,202.02. The disclosure for this sale can be found here. Insiders have sold 253,175 shares of company stock worth $18,300,495 over the last 90 days. 31.30% of the stock is owned by insiders.
A number of equities analysts recently weighed in on GHDX shares. Needham & Company LLC cut Genomic Health from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 30th. Piper Jaffray Companies cut Genomic Health from an “overweight” rating to a “neutral” rating in a report on Monday, July 29th. Barclays raised Genomic Health from an “underweight” rating to an “equal weight” rating and upped their price target for the stock from $45.00 to $72.00 in a report on Tuesday, July 30th. Canaccord Genuity cut Genomic Health from a “buy” rating to a “hold” rating and reduced their price target for the stock from $77.00 to $72.00 in a report on Tuesday, July 30th. Finally, Zacks Investment Research raised Genomic Health from a “hold” rating to a “buy” rating and set a $77.00 price target for the company in a report on Wednesday, July 31st. Ten investment analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $69.86.
Genomic Health Profile
Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.
See Also: Trading on Margin
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.